Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction

Stephen R. Kraus, Roger Dmochowski, Michael E. Albo, Lei Xu, Suzanne R. Klise, Claus Roehrborn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aims: To present the methodology, standardization techniques, and results from post hoc test-retest reproducibility analyses for a large, placebo-controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO). Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [ PdetQmax]), and test-retest reproducibility of the placebo armat baseline and endpoint. Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≤13) at 20 sites were randomized to receive either tadalafil 20mg or placebo. All men underwent non-invasive uroflow and pressure-flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of PdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure-flow parameters including PdetQmax (r = .83). Conclusions: - Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter-site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test-retest reproducibility of pressure flow measures.

Original languageEnglish (US)
Pages (from-to)741-747
Number of pages7
JournalNeurourology and Urodynamics
Volume29
Issue number5
DOIs
StatePublished - Jun 2010

Fingerprint

Lower Urinary Tract Symptoms
Urodynamics
Multicenter Studies
Clinical Trials
Pressure
Placebos
Post and Core Technique
Practice Guidelines
Terminology
Calibration
Tadalafil
Equipment and Supplies

Keywords

  • Benign prostatic obstruction
  • Lower urinary tract symptoms
  • Multicenter trials
  • Standardization
  • Tadalafil
  • Urodynamic study

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology

Cite this

Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. / Kraus, Stephen R.; Dmochowski, Roger; Albo, Michael E.; Xu, Lei; Klise, Suzanne R.; Roehrborn, Claus.

In: Neurourology and Urodynamics, Vol. 29, No. 5, 06.2010, p. 741-747.

Research output: Contribution to journalArticle

@article{bea4846f53664a029d8440578b0d7e83,
title = "Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction",
abstract = "Aims: To present the methodology, standardization techniques, and results from post hoc test-retest reproducibility analyses for a large, placebo-controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO). Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [ PdetQmax]), and test-retest reproducibility of the placebo armat baseline and endpoint. Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≤13) at 20 sites were randomized to receive either tadalafil 20mg or placebo. All men underwent non-invasive uroflow and pressure-flow studies. Numbers of invalid studies at baseline and endpoint were 9.3{\%} and 0.6{\%}, respectively. Variability of PdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure-flow parameters including PdetQmax (r = .83). Conclusions: - Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter-site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test-retest reproducibility of pressure flow measures.",
keywords = "Benign prostatic obstruction, Lower urinary tract symptoms, Multicenter trials, Standardization, Tadalafil, Urodynamic study",
author = "Kraus, {Stephen R.} and Roger Dmochowski and Albo, {Michael E.} and Lei Xu and Klise, {Suzanne R.} and Claus Roehrborn",
year = "2010",
month = "6",
doi = "10.1002/nau.20825",
language = "English (US)",
volume = "29",
pages = "741--747",
journal = "Neurourology and Urodynamics",
issn = "0733-2467",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction

AU - Kraus, Stephen R.

AU - Dmochowski, Roger

AU - Albo, Michael E.

AU - Xu, Lei

AU - Klise, Suzanne R.

AU - Roehrborn, Claus

PY - 2010/6

Y1 - 2010/6

N2 - Aims: To present the methodology, standardization techniques, and results from post hoc test-retest reproducibility analyses for a large, placebo-controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO). Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [ PdetQmax]), and test-retest reproducibility of the placebo armat baseline and endpoint. Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≤13) at 20 sites were randomized to receive either tadalafil 20mg or placebo. All men underwent non-invasive uroflow and pressure-flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of PdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure-flow parameters including PdetQmax (r = .83). Conclusions: - Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter-site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test-retest reproducibility of pressure flow measures.

AB - Aims: To present the methodology, standardization techniques, and results from post hoc test-retest reproducibility analyses for a large, placebo-controlled, multicenter trial, employing urodynamic studies (UDS) to assess the impact of daily tadalafil on men with lower urinary tract symptoms (LUTS) with or without benign prostatic obstruction (BPO). Methods: UDS implemented International Continence Society (ICS) Good Urodynamic Practice guidelines and standardized urodynamic and LUTS terminology. Further standardization procedures included: equipment calibration; a detailed procedure manual and centralized training; and implementation of a central reader. Measures included: monitoring of invalid studies, comparison of actual versus expected standard deviation (SD) for primary outcome (detrusor pressure at maximum urinary flow rate [ PdetQmax]), and test-retest reproducibility of the placebo armat baseline and endpoint. Results: Two hundred men with moderate to severe LUTS (baseline IPSS ≤13) at 20 sites were randomized to receive either tadalafil 20mg or placebo. All men underwent non-invasive uroflow and pressure-flow studies. Numbers of invalid studies at baseline and endpoint were 9.3% and 0.6%, respectively. Variability of PdetQmax was lower than anticipated based on actual versus expected SD of 15 and 30, respectively. Correlation coefficients were very good for pressure-flow parameters including PdetQmax (r = .83). Conclusions: - Multicenter clinical trials using urodynamic outcomes require additional standardized procedures to limit inter-site variability. By implementing centralized training with a detailed procedure manual and use of a central reader, we were able to limit common difficulties arising in multicenter clinical trials, as well as demonstrate good test-retest reproducibility of pressure flow measures.

KW - Benign prostatic obstruction

KW - Lower urinary tract symptoms

KW - Multicenter trials

KW - Standardization

KW - Tadalafil

KW - Urodynamic study

UR - http://www.scopus.com/inward/record.url?scp=77956813557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956813557&partnerID=8YFLogxK

U2 - 10.1002/nau.20825

DO - 10.1002/nau.20825

M3 - Article

C2 - 20151469

AN - SCOPUS:77956813557

VL - 29

SP - 741

EP - 747

JO - Neurourology and Urodynamics

JF - Neurourology and Urodynamics

SN - 0733-2467

IS - 5

ER -